|
Number of patients
|
64
|
|
Male
|
54 (84.4%)
|
|
Age (years)
|
65.4 ± 14.1
|
|
Body mass index
|
28.5 ± 4.1
|
|
High blood pressure
|
34 (53.1%)
|
|
Coronary heart disease
|
12 (18.8%)
|
|
Peripheral arterial disease
|
3 (4.7%)
|
|
Stroke
|
7 (10.9%)
|
|
Dyslipidaemia
|
34 (53.1%)
|
|
Diabetes mellitus
|
17 (26.6%)
|
|
Chronic sleep apnoea
|
9 (14.1%)
|
|
Psoriasis
|
6 (9.4%)
|
|
Ongoing diuretic treatment
|
15 (23.4%)
|
|
History of renal stones
|
11 (17.2%)
|
|
Familial history of gout
|
14 (21.9%)
|
|
eGFR (CKD-EPI/MDRD)
|
75.6 ± 25.6
|
|
CKD 3 or worse (clearance <60 ml/min)
|
16 (25.0%)
|
|
Daily alcohol consumption (g)
|
14.5 ± 22.7
|
|
Excessive sweetened beverages
|
8 (12.5%)
|
|
Excessive purine-rich foods
|
17 (26.6%)
|
|
2015 ACR/EULAR diagnosis score
|
12.8 ± 2.4
|
|
Crystal-proven gout
|
11 (17.2%)
|
|
Clinical tophi
|
21 (32.8%)
|
|
Gout duration (years)
|
12.8 ± 12.3
|
|
Number of flares per year
|
4 ± 6
|
|
Ongoing urate-lowering therapy (n)
|
43 (67.2%)
|
|
Urate-lowering therapy
| |
|
Febuxostat
|
17 (39.5%)
|
|
Allopurinol
|
24 (55.8%)
|
|
Benzbromarone
|
1 (2.3%)
|
|
Probenecid
|
1 (2.3%)
|
|
Serum uric acid level (mg/dl)
|
7.36 ± 2.55
|
